Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies
- 31 December 2005
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 31 (8) , 591-602
- https://doi.org/10.1016/j.ctrv.2005.10.001
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesBlood, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- Phase I Study of Bortezomib in Refractory or Relapsed Acute LeukemiasClinical Cancer Research, 2004
- Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Blood, 2003
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- Taking Garbage In, Tossing Cancer Out?Science, 2002
- Delayed stem cell transplantation for the management of relapsed or refractory multiple myelomaBone Marrow Transplantation, 2000
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998